Abemaciclib pharmacology and interactions in the treatment of HR+/HER2− breast cancer: a critical review
Abemaciclib (ABE) in combination with endocrine therapy represents the mainstay treatment for either endocrine-resistant metastatic or high-risk early-stage HR+/HER2− breast cancer patients. Hence, an adequate knowledge of this agent pharmacodynamic, pharmacokinetic, and of its drug–drug interaction...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
SAGE Publishing
2024-04-01
|
| Colección: | Therapeutic Advances in Drug Safety |
| Acceso en línea: | https://doi.org/10.1177/20420986231224214 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|